key: cord-1021275-1g50q60m authors: DeWald, Lisa Evans; Starr, Chloe; Butters, Terry; Treston, Anthony; Warfield, Kelly L. title: Iminosugars: a host-targeted approach to combat Flaviviridae infections date: 2020-08-05 journal: Antiviral Res DOI: 10.1016/j.antiviral.2020.104881 sha: 452cbb2ba2122e87b3d79c58c1c4a3ab0a9b6822 doc_id: 1021275 cord_uid: 1g50q60m N-linked glycosylation is the most common form of protein glycosylation and is required for the proper folding, trafficking, and/or receptor binding of some host and viral proteins. As viruses lack their own glycosylation machinery, they are dependent on the host’s machinery for these processes. Certain iminosugars are known to interfere with the N-linked glycosylation pathway by targeting and inhibiting α-glucosidases I and II in the endoplasmic reticulum (ER). Perturbing ER α-glucosidase function can prevent these enzymes from removing terminal glucose residues on N-linked glycans, interrupting the interaction between viral glycoproteins and host chaperone proteins that is necessary for proper folding of the viral protein. Iminosugars have demonstrated broad-spectrum antiviral activity in vitro and in vivo against multiple viruses. This review discuses the broad activity of iminosugars against Flaviviridae. Iminosugars have shown favorable activity against multiple members of the Flaviviridae family in vitro and in murine models of disease, although the activity and mechanism of inhibition can be virus specific. While iminosugars are not currently approved for the treatment of viral infections, their potential use as future host-targeted antiviral (HTAV) therapies continues to be investigated. DENV-1 and DENV-2 in Vero, Huh-7, and THP-1 cells, the IC 50 varied, ranging from 0.75 -51 288 µM depending on the serotype, MOI, and cell type (Watanabe et al., 2016) . 289 The variable response of flaviviruses to iminosugar treatment was also recognized when the 290 antiviral activity of CAST was evaluated against multiple viruses in parallel, including DENV, 291 WNV, and YFV, in BHK-21 cells (Whitby et al., 2005) . CAST treatment demonstrated inhibition 292 against all four DENV serotypes, with >95% reduction in the number of infected cells at 50 µM, 293 as measured by immunostaining and flow cytometry, but resulted in minimal to no inhibitory 294 effect against WNV at concentrations of up to 500 µM. Decreased inhibition of YFV was also 295 observed compared to DENV, although there was still a 93% reduction at 500 µM relative to 296 untreated cells. Plaque assays of supernatants confirmed this differential inhibitory response to 297 treatment. Cells exposed to 50 µM of CAST had a 910-fold reduction in the production of 298 infectious DENV particles, but only a 1.7-and 6.8-fold reduction was observed for WNV and 299 YFV, respectively (Whitby et al., 2005) . Despite the lack of antiviral activity of the bicyclic The difference in sensitivity to iminosugar treatment between DENV and other flaviviruses 305 was further demonstrated in HEK293 cells treated with IHVR-19029. The IC 50 was 12.5 times 306 higher for YFV than DENV, and 17.6 times higher for ZIKV than DENV (Ma et al., 2018a) . 307 Iminosugar efficacy has also been assessed against JEV in two published studies, both 308 demonstrating a similar trend in antiviral activity when compared to DENV (Wu et al., 2002) . The 309 DNJ derivative, NN-DNJ, which is known to have more potent antiviral activity than DNJ, 310 inhibited the production of infectious JEV and DENV-2 in BHK-21 cells, however, the reduction was much greater at lower concentrations for DENV-2 compared to JEV. Other iminosugars 312 (CAST, DNJ, and DMJ) had minimal to no impact on JEV replication, reducing viral RNA or 313 infectious particle secretion by only ≤10-fold, but inhibited DENV secretion by up to 10 6 plaque 314 forming units (pfu). Similarly, NN-DNJ (100 µM) also reduced the secretion of infectious KUNV 315 particles by more than 10 3 pfu in Vero cells despite DNJ having no inhibitory effect when tested 316 at the same concentration (Mackenzie et al., 2001) . It is possible that differences in the number 317 and/or location of glycosylation sites within viral proteins may contribute to the range in antiviral 318 activity of iminosugars observed against different flaviviruses (Miller et al., 2018) . 319 Depending on the structure, iminosugars are capable of differentially inhibiting glycolipid or 320 glycoprotein processing enzymes. The ability of some iminosugars to inhibit glycolipid 321 processing was originally thought to contribute to the anti-DENV activity of this class of and bicyclic glucose-mimicking iminosugars inhibit glycoprotein processing, but only monocyclic compounds also inhibit glycolipid processing enzymes. Galactose-mimicking iminosugars 337 inhibited glycolipid processing but not glycoprotein processing. Interestingly, the level of 338 glucosyltransferase enzymatic inhibition correlated with the length of the alkyl tail, despite 339 whether the iminosugar mimicked glucose or galactose, with longer tails having stronger Only the glucose-mimicking iminosugars that inhibited enzymes required for either glycoprotein 345 processing, or both glycoprotein and glycolipid processing, were efficacious against DENV-2, 346 whereas iminosugars with a galactose-like configuration had no measurable effect on the virus. 347 In a similar study, the glucose-mimicking iminosugar, UV-4B (MON-DNJ), inhibited the 348 enzymatic activity of both α-glucosidase I and II, but when an isomer of UV-4B designed to have 349 a galactose-like configuration was tested, α-glucosidase I and II inhibition was lost (Warfield et 350 al., 2016b) . MDMs treated with UV-4B containing either a glucose-or galactose-like 351 configuration had reduced levels of GM3; however, only UV-4B with a glucose-like configuration 352 generated FOS and was active against DENV, while the galactose-mimicking isomer lacking α -353 glucosidase inhibition was not efficacious against the virus. channel activity in a dose-dependent manner (Pavlovic et al., 2003) . Interestingly, DENV-2 and JEV, which do not encode for the p7/p13 protein, are not inhibited by DGJ derivatives (Wu et al., 412 2002) . 413 While many of the initial studies used BVDV as a surrogate for HCV, the use of HCV virus 414 like particles (VLPs) and the later developed in vitro HCV infectivity systems helped to confirm 415 the anti-HCV activity of iminosugars against multiple genotypes (Figure 1 and Table 2) . containing the p7 F25A polymorphism was exposed to NN-DNJ or NN-DGJ treatment, minimal 427 to no effect was observed on virus secretion, whereas secretion of wild-type JFH-1 virus was 428 largely inhibited following exposure to the iminosugars. were infected intravenously with 7 x 10 7 pfu DENV-1 (2402 strain) after being exposed to the 516 infections, although these studies did not proceed further than Phase II (Fischl et al., 1994) . 528 Prior to the recent development and approval of highly efficacious direct-acting antivirals against 529 HCV (discussed in more detail below), the standard therapy for patients consisted of a less 530 effective combination of interferon (IFN) and ribavirin, which could be associated with multiple, both good examples of the differential effects that can be observed following treatment with 589 iminosugars. Extensive research has been performed evaluating the effect of iminosugars 590 against influenza virus, which is discussed further in a separate review (Plummer et al., 2015) . STT3B knockout cell lines, respectively, suggesting the mechanism is at least partially 718 independent of viral protein glycosylation Instead, the OST complex was found to interact with 719 viral NS proteins of the RNA replication complex, demonstrating that OST plays a structural role 720 though a physical interaction with a viral protein that is required for DENV RNA replication. The FDA-approved compounds chloroquine, ivermectin, prednisolone, and lovastatin have 773 also been evaluated in clinical trials for the treatment of DENV infections or for their ability to 774 relieve associated symptoms without exacerbating infectivity. These compounds were 775 considered to be promising candidates with the potential to be fast-tracked for approval because 776 of their known safety profiles. Unfortunately, in a majority of these clinical studies, treatment did 777 not provide a measurable benefit or was associated with adverse events. 778 Unlike for flaviviruses, significant advancement has been made for HCV antiviral drug 779 development in the last 5 -10 years, with recent approval of multiple direct-acting antivirals. iminosugar, in a combination cocktail could further reduce the potential for viruses to mutate and 804 no longer respond to the approved treatment. One of the practical challenges that needs to be considered when developing novel 806 iminosugars as HTAVs is that, because both the virus and the host depend on ER glucosidases 807 for glycan processing, the development of potent compounds could potentially have a negative 808 impact on the host. Regulatory agency concerns around this issue have likely slowed 809 development of HTAV therapies compared to direct-acting antivirals. However, good therapeutic 810 window and high tolerability have been observed for some iminosugars in animal infection 811 models, suggesting that viral proteins may be more susceptible to enzyme inhibition than host 812 proteins. It is likely viral proteins are being synthesized at an exponentially higher rate compared Gu, B., Mason, P., Wang, L., Norton, P., Bourne, N., Moriarty, R., Mehta 999 Functional Analysis of Glycosylation of Zika Virus Envelope Protein Resistance mutations define specific 1002 antiviral effects for inhibitors of the hepatitis C virus p7 ion channel Structure and Function of the 1004 Hepatitis C Virus Envelope Glycoproteins E1 and E2: Antiviral and Vaccine Targets. ACS Infect 1005 Dis Sequence differences between glycosylated and non-1007 glycosylated Asn-X-Thr/Ser acceptor sites: implications for protein engineering Role of N-linked glycans in the functions of hepatitis C virus envelope glycoproteins Glycosylation of hepatitis C virus envelope proteins Role of 1015 the N-linked glycans of the prM and E envelope proteins in tick-borne encephalitis virus particle 1016 secretion Genotype-1018 dependent sensitivity of hepatitis C virus to inhibitors of the p7 ion channel The envelope glycoproteins of dengue 1 and 1061 dengue 2 viruses grown in mosquito cells differ in their utilization of potential glycosylation sites Hepatitis C virus p7 1064 and NS2 proteins are essential for production of infectious virus 1066 Inhibition of host ER glucosidase activity prevents Golgi processing of virion-associated bovine 1067 viral diarrhea virus E2 glycoproteins and reduces infectivity of secreted virions Regulation of N-linked core glycosylation: 1070 use of a site-directed mutagenesis approach to identify Asn-Xaa-Ser/Thr sequons that are poor 1071 oligosaccharide acceptors Antibody-dependent enhancement of severe dengue disease in humans Genetic determinants of dengue type 4 1076 virus neurovirulence for mice ToP-DNJ, a Selective Inhibitor of Endoplasmic Reticulum alpha-1079 A single N-1081 linked glycosylation site in the Japanese encephalitis virus prM protein is critical for cell type-1082 specific prM protein biogenesis, virus particle release, and pathogenicity in mice Proper maturation of the Japanese encephalitis virus envelope 1085 glycoprotein requires cosynthesis with the premembrane protein Assembly of asparagine-linked oligosaccharides Structure of 1090 dengue virus: implications for flavivirus organization, maturation, and fusion Effect of catanospermine, 1-deoxynojirimycin or 1-1092 deoxymannojirimycin on biological and functional activities of Japanese encephalitis virus in 1093 porcine stable kidney cells G 1095 protein-coupled receptor kinase 2 promotes flaviviridae entry and replication Both E protein glycans adversely affect 1098 dengue virus infectivity but are beneficial for virion release Changes in the dengue virus major envelope protein on 1100 passaging and their localization on the three-dimensional structure of the protein The 1103 flavivirus precursor membrane-envelope protein complex: structure and maturation Dengue Virus Hijacks a Noncanonical Oxidoreductase Function of a Cellular 1107 Oligosaccharyltransferase Complex The ins and outs of hepatitis C virus entry and assembly The IMPORTance of the Nucleus during Flavivirus 1111 Replication Oligosaccharyltransferase inhibition induces senescence in RTK-driven tumor cells Folding and dimerization of tick-borne 1117 encephalitis virus envelope proteins prM and E in the endoplasmic reticulum 1120 Intracellular assembly and secretion of recombinant subviral particles from tick-borne 1121 encephalitis virus Current Status of Dengue Therapeutics Research 1123 and Development Efficacy and safety of celgosivir in patients with dengue fever 1128 (CELADEN): a phase 1b, randomised, double-blind A CRISPR-Based Screen Identifies Genes Essential for West-1132 Nile-Virus-Induced Cell Death Enhancing the antiviral potency of ER alpha-glucosidase inhibitor IHVR-19029 against 1136 hemorrhagic fever viruses in vitro and in vivo Host 1138 Factor SPCS1 Regulates the Replication of Japanese Encephalitis Virus through Interactions 1139 with Transmembrane Domains of NS2B Assembly and maturation of the flavivirus Kunjin virus 1141 appear to occur in the rough endoplasmic reticulum and along the secretory pathway, 1142 respectively Treating viral hepatitis C: efficacy, side 1144 effects, and complications Genetic dissection of Flaviviridae 1147 host factors through genome-scale CRISPR screens Comparative Analysis of 1149 Protein Glycosylation Pathways in Humans and the Fungal Pathogen Candida albicans The TIM and TAM families of phosphatidylserine receptors 1153 mediate dengue virus entry Imino sugars that are less toxic but more potent as antivirals, in vitro, 1156 compared with N-n-nonyl DNJ Oseltamivir-resistant influenza virus A (H1N1), Europe, 2007-08 season Preparation, biochemical characterization and biological properties of 1163 radiolabelled N-alkylated deoxynojirimycins Membrane disruption and cytotoxicity 1165 of hydrophobic N-alkylated imino sugars is independent of the inhibition of protein and lipid 1166 glycosylation Iminosugars 1168 counteract the downregulation of the interferon gamma receptor by dengue virus Liposome-mediated delivery of iminosugars enhances efficacy against 1172 dengue virus in vivo Mechanisms of Antiviral Activity of Iminosugars 1174 Against Dengue Virus Glycoproteins form mixed disulphides with oxidoreductases 1176 during folding in living cells Essential role of dengue virus 1178 envelope protein N glycosylation at asparagine-67 during viral propagation Role of 1181 N-glycosylation on Zika virus E protein secretion, viral assembly and infectivity Structure of 1184 West Nile virus Mutagenesis of the N-linked 1186 glycosylation sites of the yellow fever virus NS1 protein: effects on virus replication and mouse 1187 neurovirulence A randomized, 1192 double-blind placebo controlled trial of balapiravir, a polymerase inhibitor, in adult dengue 1193 patients Balapiravir plus peginterferon alfa-2a 1197 (40KD)/ribavirin in a randomized trial of hepatitis C genotype 1 patients Rewiring cellular networks 1199 by members of the Flaviviridae family Analysis of fluorescently labeled glycosphingolipid-derived 1202 oligosaccharides following ceramide glycanase digestion and anthranilic acid labeling Characterization of influenza virus variants 1206 induced by treatment with the endonuclease inhibitor baloxavir marboxil Biogenesis of hepatitis C virus envelope 1208 glycoproteins The combination of 1210 interferon alpha-2b and n-butyl deoxynojirimycin has a greater than additive antiviral effect upon 1211 production of infectious bovine viral diarrhea virus (BVDV) in vitro: implications for hepatitis C 1212 virus (HCV) therapy Flaviviridae Replication Organelles: Oh, What a Tangled 1214 Web We Weave The hepatitis C virus p7 protein forms an ion channel that is inhibited by long-alkyl-chain 1217 iminosugar derivatives An iminosugar with potent inhibition of dengue virus infection in vivo Uncovering Flavivirus 1223 Host Dependency Factors through a Genome-Wide Gain-of-Function Screen Organization of the native ribosome-1225 translocon complex at the mammalian endoplasmic reticulum membrane N-butyldeoxynojirimycin is a novel 1228 inhibitor of glycolipid biosynthesis N-1230 butyldeoxygalactonojirimycin inhibits glycolipid biosynthesis but does not affect N-linked 1231 oligosaccharide processing Dengue Virus 1234 Evolution under a Host-Targeted Antiviral Cryo-EM reconstruction of 1237 dengue virus in complex with the carbohydrate recognition domain of DC-SIGN 1243 Functional and antigenic domains of the dengue-2 virus nonstructural glycoprotein NS-1 Inhibitors of endoplasmic reticulum alpha-glucosidases potently suppress hepatitis C 1247 virus virion assembly and release Repurposing of Miglustat to inhibit the coronavirus 1250 Severe Acquired Respiratory Syndrome SARS-CoV-2. 1251 doi Celgosivir treatment misfolds dengue virus NS1 protein, induces 1254 cellular pro-survival genes and protects against lethal challenge mouse model Virion-associated 1257 phosphatidylethanolamine promotes TIM1-mediated infection by Ebola, dengue, and West Nile 1258 viruses Robust antiviral activity of R1626, a novel nucleoside analog: 1261 a randomized, placebo-controlled study in patients with chronic hepatitis C Glycosylation, hypogammaglobulinemia, and resistance 1269 to viral infections The p7 polypeptide of hepatitis C virus is critical for infectivity and contains functionally 1272 important genotype-specific sequences Identification of Zika Virus and Dengue Virus Dependency Factors using Functional Iminosugars Inhibit Dengue Virus Production via Inhibition of ER Alpha-1280 Glucosidases--Not Glycolipid Processing Enzymes Malectin: a novel carbohydrate-binding 1283 protein of the endoplasmic reticulum and a candidate player in the early steps of protein N-1284 glycosylation A dengue fever viremia 1286 model in mice shows reduction in viral replication and suppression of the inflammatory response 1287 after treatment with antiviral drugs Cotranslational and posttranslocational N-1289 glycosylation of proteins in the endoplasmic reticulum ICTV Virus Taxonomy 1292 Profile: Flaviviridae Back to (non-)Basics: An Update on Neutral and Charge-Balanced Glycosidase Hepatitis B virus large and middle 1297 glycoproteins are degraded by a proteasome pathway in glucosidase-inhibited cells but not in 1298 cells with functional glucosidase enzyme N-linked 1300 glycosylation of dengue virus NS1 protein modulates secretion, cell-surface expression, 1301 hexamer stability, and interactions with human complement Proteolytic activation of tick-borne 1303 encephalitis virus by furin In vivo therapeutic 1305 protection against influenza A (H1N1) oseltamivir-sensitive and resistant viruses by the 1306 iminosugar UV-4 Hepatitis C virus p7 protein is crucial for assembly and release of infectious virions Flavivirus membrane fusion 1314 Detection of influenza A(H3N2) viruses exhibiting reduced susceptibility to the novel cap-1315 dependent endonuclease inhibitor baloxavir in Japan Influenza A(H3N2) virus 1320 exhibiting reduced susceptibility to baloxavir due to a polymerase acidic subunit I38T 1321 substitution detected from a hospitalised child without prior baloxavir treatment 1325 Effects of short-course oral corticosteroid therapy in early dengue infection in Vietnamese 1326 patients: a randomized, placebo-controlled trial A randomized controlled trial of chloroquine for the treatment of dengue in Vietnamese 1329 adults Challenges and perspectives of 1331 direct antivirals for the treatment of hepatitis C virus infection The ER membrane protein complex promotes biogenesis of 1334 sterol-related enzymes maintaining cholesterol homeostasis Molecular and 1336 biological characterization of a non-glycosylated isolate of St Louis encephalitis virus The Iminosugar UV-4 is a Broad Inhibitor of Influenza A 1340 and B Viruses ex Vivo and in Mice A Novel Iminosugar UV-12 with 1343 Activity against the Diverse Viruses Influenza and Dengue (Novel Iminosugar Antiviral for 1344 Influenza and Dengue) Inhibition of 1349 endoplasmic reticulum glucosidases is required for in vitro and in vivo dengue antiviral activity 1350 by the iminosugar UV-4 Lack of selective 1353 resistance of influenza A virus in presence of host-targeted antiviral, UV-4B Optimizing 1355 celgosivir therapy in mouse models of dengue virus infection of serotypes 1 and 2: The search 1356 for a window for potential therapeutic efficacy Exploitation of glycosylation in 1358 enveloped virus pathobiology Dose-and schedule-dependent protective efficacy of celgosivir in 1361 a lethal mouse model for dengue virus infection informs dosing regimen for a proof of concept 1362 clinical trial Composition and three-dimensional 1365 architecture of the dengue virus replication and assembly sites Castanospermine, a potent inhibitor of dengue virus infection in vitro and in vivo Action of celgosivir (6 O-butanoyl 1370 castanospermine) against the pestivirus BVDV: implications for the treatment of hepatitis C Lovastatin for the Treatment of Adult Patients With 1375 Dengue: A Randomized, Double-Blind, Placebo-Controlled Trial Dengue virus type 2 1378 recognizes the carbohydrate moiety of neutral glycosphingolipids in mammalian and mosquito 1379 cells Newly synthesized dengue-2 virus 1381 nonstructural protein NS1 is a soluble protein but becomes partially hydrophobic and 1382 membrane-associated after dimerization Iminosugars in combination with interferon and ribavirin permanently 1385 eradicate noncytopathic bovine viral diarrhea virus from persistently infected cells Small 1389 molecules targeting severe acute respiratory syndrome human coronavirus Antiviral effects of an 1392 iminosugar derivative on flavivirus infections N-linked glycan in tick-1396 borne encephalitis virus envelope protein affects viral secretion in mammalian cells, but not in 1397 tick cells 1399 Association of the pr peptides with dengue virus at acidic pH blocks membrane fusion Structure of the immature dengue virus at low pH primes 1403 proteolytic maturation Specific requirements for 1405 elements of the 5' and 3' terminal regions in flavivirus RNA synthesis and viral replication Design, synthesis, and biological evaluation of N-alkylated 1409 deoxynojirimycin (DNJ) derivatives for the treatment of dengue virus infection N-glycosylation of the 1412 premembrane protein of Japanese encephalitis virus is critical for folding of the envelope protein 1413 and assembly of virus-like particles Cellular Targets for the Treatment of Flavivirus 1415 Infections Protective effect of 1417 homonojirimycin from Commelina communis (dayflower) on influenza virus infection in mice A 1421 CRISPR screen defines a signal peptide processing pathway required by flaviviruses Visualization of membrane protein 1425 domains by cryo-electron microscopy of dengue virus Structures and Functions of 1427 the Envelope Glycoprotein in Flavivirus Infections Inhibition of endoplasmic reticulum-resident glucosidases 1430 impairs severe acute respiratory syndrome coronavirus and human coronavirus NL63 spike 1431 protein-mediated entry by altering the glycan processing of angiotensin I-converting enzyme 2 Imino sugars inhibit the formation and secretion of bovine 1435 viral diarrhea virus, a pestivirus model of hepatitis C virus: implications for the development of 1436 broad spectrum anti-hepatitis virus agents Reduction in viral RNA and infectious virus secretion measured in MDBK cells 4c, 5d X X BVDV in MDBK cells and DENV-2 in BHK-21 cells: Activity of individual compounds comparable against DENV and BVDV SP-150; SP-156 SP-159 SP-164; SP-165 SP-166 SP-168; SP-187 X Virus yield reduction using MDBK cells: SP-165, SP-166 We sincerely thank Christine Butler for reviewing and editing early drafts of the manuscript and 852Kezia Suwintono and Hemin Chon for assisting with preparing figures and tables. 853 NN-DNJ (N-nonyl-DNJ / UV-2 / DNJ Derivative 6) X X X X X X BVDV in MBDK cells: Range in IC50s depending on assay and publication, with most ranging between 3-115 µM, CC 50 s mostly >100 uM DENV-2 in multiple cell lines: IC 50 =1-9 µM, CC 50 =20-317 µM; interfered with prM, E, and NS1 protein interaction with calnexin in BHK-21 cells HCV in Huh7/Huh7.5/Huh7-Lunet cells: Multiple genotypes evaluated. Dose dependent decrease in production of infectious particles. Reduced electrophoretic mobility shift of E1 and E2 glycoproteins (JFH1 replicon system); inhibition of p7 function for most genotypes tested except for JFH-1/452 (genotype 3a) in which a lower inhibition of infectious particle secretion (only ~40% reduction at 50 µm) and minimal reduction in p7 function were observed. In Sf9 cells using HCV VLPs, E1 and E2 glycoproteins accumulated in ER and had reduced mobility shifts; VLPs produced had reduced binding to huh7 cells. References are provided in Figure 5 and details for each study are included in Supplemental Table 2 .